- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Propanc Biopharma, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 24.03. | Propanc Biopharma, Inc.: Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain | 579 | GlobeNewswire (Europe) | MELBOURNE, Australia, March 24, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for... ► Artikel lesen | |
| 12.03. | Propanc Biopharma, Inc.: Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy | 331 | GlobeNewswire (Europe) | MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for... ► Artikel lesen | |
| 10.03. | Propanc Biopharma contracts FyoniBio for drug assay development | 2 | Investing.com | ||
| 10.03. | Propanc Biopharma signs contract for Phase 1b cancer trial assay | 2 | Investing.com | ||
| 10.03. | Propanc Biopharma beauftragt FyoniBio mit Entwicklung eines Wirkstoff-Assays | 1 | Investing.com Deutsch | ||
| 10.03. | Propanc Biopharma beauftragt FyoniBio mit Assay für Phase-1b-Krebsstudie | 2 | Investing.com Deutsch | ||
| PROPANC BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 10.03. | Propanc Biopharma, Inc.: Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study | 1 | GlobeNewswire (USA) | ||
| 03.03. | Propanc Biopharma, Inc.: Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models | 169 | GlobeNewswire (Europe) | MELBOURNE, Australia, March 03, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for... ► Artikel lesen | |
| 26.02. | Propanc Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.02. | Propanc Biopharma, Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 18.02. | Propanc Biopharma, Inc. GAAP EPS of -$0.30 | 1 | Seeking Alpha | ||
| 18.02. | Propanc Biopharma files four new patent applications for cancer treatment | 1 | Investing.com | ||
| 18.02. | Propanc Biopharma, Inc.: Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results | 284 | GlobeNewswire (Europe) | MELBOURNE, Australia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel treatments for recurrent and... ► Artikel lesen | |
| 17.02. | Propanc Biopharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 05.02. | Propanc Biopharma, Inc.: Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market | 2 | GlobeNewswire (USA) | ||
| 02.02. | Propanc Biopharma, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 27.01. | Propanc Biopharma, Inc.: Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months - Strengthening Global Protection for Breakthrough Proenzyme Formulations | 5 | GlobeNewswire (USA) | ||
| 20.01. | Propanc Biopharma files new patent for synthetic cancer treatment | 2 | Investing.com | ||
| 20.01. | Propanc Biopharma meldet neues Patent für synthetische Krebstherapie an | - | Investing.com Deutsch |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,440 | +0,93 % | EQS-News: Evotec SE: Evotec gibt Ergebnisse für das vierte Quartal und Gesamtjahr 2025 bekannt: Grundlage für profitables Wachstum | EQS-News: Evotec SE
/ Schlagwort(e): Jahresergebnis
Evotec gibt Ergebnisse für das vierte Quartal und Gesamtjahr 2025 bekannt: Grundlage für profitables Wachstum
08.04.2026... ► Artikel lesen | |
| QIAGEN | 35,885 | -0,08 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| AMGEN | 296,75 | -0,29 % | BeOne wins China approval for Amgen's lung cancer drug Imdelltra | ||
| BIOFRONTERA | 2,480 | -3,12 % | BIOFRONTERA AG im Abwärtsmodus - ruhige Einordnung | ||
| CRISPR THERAPEUTICS | 48,475 | +0,66 % | 2 Billion Reasons to Love CRISPR Therapeutics Right Now | ||
| BIONXT SOLUTIONS | 0,306 | +2,34 % | BioNxt beginnt mit der GMP-konformen Herstellung eines sublingualen Cladribin-Films in klinischer Qualität zur Behandlung von Multipler Sklerose (MS) | VANCOUVER, BC / ACCESS Newswire /
14. April 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FWB:BXT), ein innovatives
Biowissenschaftsunternehmen, das... ► Artikel lesen | |
| NOVONESIS | 51,86 | +0,27 % | Novonesis To Acquire Thailand Production Facility For Around $50 Mln | WASHINGTON (dpa-AFX) - Novozymes A/S, Novonesis (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B), a biotechnology company, on Wednesday announced an agreement to acquire a production facility... ► Artikel lesen | |
| TEMPUS AI | 42,390 | +0,90 % | Tempus AI Expands Collaboration With Gilead Sciences To Maximize Insights In Oncology Pipeline | FOSTER CITY (dpa-AFX) - Healthcare technology company Tempus AI, Inc. (TEM) Thursday announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (GILD) to build and advance its... ► Artikel lesen | |
| GENMAB | 247,00 | +0,20 % | Genmab Reports Strong Q1 DARZALEX Sales Near $4 Bln | WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) on Tuesday reported global net trade sales of $3.964 billion for DARZALEX (daratumumab) in the first quarter of 2026, according to company announcements.... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| IMMUNITYBIO | 6,250 | -2,95 % | ImmunityBio, Inc. (IBRX) Posts Strong Preliminary Q1 Sales on ANKTIVA Momentum | ||
| TME PHARMA | 0,057 | -0,18 % | TME Pharma NV: TME Pharma extends financial runway to over 12 months | TME Pharma extends financial runway to over 12 months Berlin, Germany, March 9, 2025, 08.00am CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,540 | 0,00 % | Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform | NEW YORK and SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion... ► Artikel lesen | |
| CYTODYN | 0,290 | 0,00 % | CytoDyn Inc.: CytoDyn to Present at the AACR Annual Meeting 2026 | ||
| IMMUNIC | 0,990 | -0,60 % | EQS-News: Immunic AG: Immunic to Participate in Scientific and Medical Conferences in April | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Scientific and Medical Conferences in April
09.04.2026 / 12:30 CET/CEST
The issuer is solely responsible... ► Artikel lesen |
Das Unternehmen PROPANC BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,096 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROPANC BIOPHARMA INC finden Sie auf Wallstreet Online.